Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Degranulation of basophils after incubation with allergen in chidren with pollinosis and dust mite allergy Source: Eur Respir J 2001; 18: Suppl. 33, 450s Year: 2001
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Evaluation of specific IgE to recombinant pollen allergens in asthmatic patients with specific IgE to phleum pratense Source: Eur Respir J 2001; 18: Suppl. 33, 434s Year: 2001
The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006
Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens. Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Adherence to sublingual immunotherapy in patients allergic to mites Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
IgE specific for recombinant grass pollen allergens in allergic respiratory disease Source: Eur Respir J 2005; 26: Suppl. 49, 380s Year: 2005
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006